SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00010000.0%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (568)5/23/1999 10:47:00 PM
From: Biomaven  Read Replies (1) of 1494
 
Neuroinvestment:

Thanks for the royalty numbers on memantine.

Wouldn't even 8% of the royalties still be very significant for a pico-cap like NTII? If Merz were to license memantine to a pharma for say a 25% royalty, then NTII would end up with 2% of what could easily be a billion dollar drug.

One worry I've always had about memantine is if it works so well, how come it's not a big seller in Europe? Do you know if it is actually on the market and being promoted?

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News